NASDAQ$LQDA
Liquidia Corporation · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Liquidia reported financial results for the second quarter of 2023 and provided a corporate update.
Liquidia reported revenue of $4.8 million for the second quarter of 2023, an increase from $3.9 million in the same period last year. The net loss for the quarter was $23.5 million, or $0.36 per share, compared to a net loss of $9.4 million, or $0.15 per share, for the second quarter of 2022. Cash totaled $88.2 million as of June 30, 2023.
- Advanced litigation with United Therapeutics, with only one patent remaining gating to final approval for YUTREPIA.
- Submitted amendment to add PH-ILD indication to the YUTREPIA new drug application.
- Expanded pipeline through partnership with Pharmosa Biopharm to develop L606 in North America.
- Revenue increased to $4.8 million, primarily due to the promotion agreement with Sandoz Inc.
Headline financials
Revenue & EPS history
Liquidia · Revenue · Quarterly
$4.79M
Revenue by segment
Liquidia · $3.7M total across 1 segment · Q3 2023
- Promotion Agreement$3.7M+15.6%100.0%
Forward guidance
Liquidia plans to prepare for the potential launch of YUTREPIA for PAH and PH-ILD. Awaits FDA input from a Type B meeting later this year, Liquidia intends to initiate a Phase 3 randomized, placebo-controlled study in 2024 to evaluate treatment of PH-LD patients with L606.
Tailwinds
- Potential FDA approval of YUTREPIA for PAH and PH-ILD
- Advancement of L606 through Phase 3 study
- Opportunity to expand the treatment options for pulmonary hypertension patients
- Strong cash position to support ongoing operations
- Positive court affirmation regarding patent invalidity
Headwinds
- Ongoing litigation with United Therapeutics
- Uncertainty regarding the timing of final FDA approval for YUTREPIA
- Dependence on Sandoz for revenue from Treprostinil Injection
- Increased research and development expenses
- Increased general and administrative expenses
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2023
+3.4%
Avg return
Earnings day
+5.4%
Avg return
5 days after
+1.7%
Avg return
30 days after
60%
18 / 30 earnings
Positive
+31.8%
Q2 2022
Best reaction
-13.3%
Q2 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +25.4% | +34.5% | — | |
| Q4 2025 | +0.4% | +12.9% | +9.6% | |
| Q3 2025 | +8.8% | +7.1% | +38.5% | |
| Q1 2025 | -1.0% | +3.0% | +16.8% | |
| Q4 2024 | +1.2% | +6.2% | -6.9% | |
| Q3 2024 | -5.6% | -7.6% | +2.7% | |
| Q2 2024 | +2.9% | +10.4% | -17.7% | |
| Q1 2024 | -0.8% | +5.4% | +10.4% | |
| Q4 2023 | +9.6% | +11.3% | -0.2% | |
| Q3 2023 | -1.0% | -4.4% | +9.8% | |
| Q2 2023 | -6.3% | -8.9% | -7.5% | |
| Q1 2023 | +5.0% | +7.8% | +26.1% | |
| Q4 2022 | +13.5% | +13.2% | +6.3% | |
| Q3 2022 | +0.8% | -0.4% | +14.6% | |
| Q2 2022 | +31.8% | +34.5% | +9.9% | |
| Q1 2022 | +7.7% | +21.9% | -17.0% | |
| Q4 2021 | +11.2% | +9.7% | -17.8% | |
| Q3 2021 | +9.9% | +9.7% | +3.1% | |
| Q2 2021 | -0.8% | +11.8% | +16.4% | |
| Q1 2021 | -0.7% | +0.0% | -0.7% | |
| Q4 2020 | -7.4% | -6.6% | +2.2% | |
| Q3 2020 | +0.7% | -12.7% | -36.9% | |
| Q2 2020 | -13.3% | -8.5% | -23.3% | |
| Q1 2020 | +8.0% | +8.7% | +13.4% | |
| Q4 2019 | -1.5% | +1.7% | +54.5% | |
| Q3 2019 | +5.2% | +0.6% | +6.4% | |
| Q2 2019 | +6.4% | -0.7% | -40.6% | |
| Q1 2019 | -3.0% | -0.4% | +2.6% | |
| Q4 2018 | +3.0% | +3.1% | -43.8% | |
| Q3 2018 | -9.2% | -1.3% | +19.4% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro